Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort

Atherosclerosis

Volumn 214, Issue 1, 2011, Pages 196-202

  Williams, Paul T ^a   Feldman, Daniel E ^a  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

High density lipoproteins; Lipoprotein; Prevention; Risk factors

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVASCULARIZATION; RISK FACTOR; STRUCTURED QUESTIONNAIRE;

AGED; CHOLESTEROL, HDL; COHORT STUDIES; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; QUESTIONNAIRES;

EID: 78650851475     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.10.024     Document Type: Article

References (32)

1. Musliner T.A., Krauss R.M. Lipoprotein subspecies and risk of coronary disease. Clin Chem 1988, 34:B78-83.
2. Gofman J.W., Lindgren F., Elliott H., et al. The role of lipids and lipoproteins in atherosclerosis. Science 1950, 111:166-171.
3. DeLalla O.F., Gofman J.W. Ultracentrifugal analysis of serum lipoproteins. Methods Biochem Anal 1954, 1:459-478.
4. Gofman J.W. Serum lipoproteins and the evaluation of atherosclerosis. Ann N Y Acad Sci 1956, 64:590-595.
5. Lindgren F.T., Silvers A., Jutaglr R., Layshot L., Bradley D.D. A comparison of simplified methods for lipoprotein quantification using the analytic ultracentrifuge as a standard. Lipids 1977, 12:278-282.
6. Hulley S.B., Cook S.G., Wilson W.S., et al. Quantitation of serum lipoproteins by electrophoresis on agarose gel: standardization in lipoprotein concentration units (mg-100ml) by comparison with analytical ultracentrifugation. J Lipid Res 1971, 12:420-433.
7. Kahlon T.S., Glines L.A., Lindgren F.T. Analytic ultracentrifugation of plasma lipoproteins. Methods Enzymol 1986, 129:26-45.
8. Gofman J.W., Young W., Tandy R. Ischemic heart disease, atherosclerosis, and longevity. Circulation 1966, 34:679-697.
9. Colman D.M., McPhee A.F. An improved method for determination of total serum cholesterol. Am J Clin Pathol 1956, 26:181-186.
10. Fortmann S.P., Varady A.N. Effects of a community-wide health education program on cardiovascular disease morbidity and mortality: the Stanford Five-City Project. Am J Epidemiol 2000, 152:316-323.
11. NCEP ATP-III Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
12. Warnick G.R., Bengtsson B., Albers J.J. Quantitation of high-density lipoprotein subclasses after separation by dextran sulfate and Mg2+ precipitation. Clin Chem 1982, 28:1574.
13. Williams P.T., Krauss R.M., Vranizan K.M., et al. Associations of lipoproteins and apolipoproteins with gradient gel electrophoresis estimates of high density lipoprotein subfractions in men and women. Arterioscler Thromb 1992, 12:332-340.
14. Sharrett A.R., Ballantyne C.M., Coady S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001, 104:1108-1113.
15. Fujimoto W.Y., Bergstrom R.W., Boyko E.J., et al. Visceral adiposity and incident coronary heart disease in Japanese-American men. The 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study. Diabetes Care 1999, 22:1808-1812.
16. Lamarche B., Moorjani S., Cantin B., et al. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997, 17:1098-1105.
17. Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., Hennekens C.H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991, 325:373-381.
18. Salonen J.T., Salonen R., Seppänen K., Rauramaa R., Tuomilehto J. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 1991, 84:129-139.
19. Laakso M., Lehto S., Penttilä I., Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993, 88:1421-1430.
20. Sweetnam P.M., Bolton C.H., Yarnell J.W., et al. Associations of the HDL2 and HDL3 cholesterol subfractions with the development of ischemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1994, 90:769-774.
21. Mora S., Otvos J.D., Rifai N., et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009, 119:931-939.
22. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006, 113:1556-1563.
23. Musunuru K., Orho-Melander M., Caulfield M.P., et al. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol 2009, 29:1975-1980.
24. Johansson J., Olsson A.G., Bergstrand L., et al. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report. Arterioscler Thromb Vasc Biol 1995, 15:1049-1056.
25. Johansson J., Carlson L.A., Landou C., Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 1991, 11:174-182.
26. Tornvall P., Karpe F., Proudler A., et al. High-density lipoprotein: relations to metabolic parameters and severity of coronary artery disease. Metabolism 1996, 45:1375-1382.
27. Watanabe H., Söderlund S., Soro-Paavonen A., et al. Decreased high-density lipoprotein (HDL) particle size, prebeta-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. Arterioscler Thromb Vasc Biol 2006, 26:897-902.
28. Levy R.I., Brensike J.F., Epstein S.E., et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984, 69:313-324.
29. Cooper R.S., Liao Y., Rotimi C. Is hypertension more severe among U.S. blacks, or is severe hypertension more common?. Ann Epidemiol 1996, 6:173-180.
30. D'Agostino R.B., Grundy S., Sullivan L.M., Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001, 28:180-187. CHD Risk Prediction Group.
31. Nordestrgaad B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
32. Bansal S., Buring J.E., Rifai N., et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.